

Revised Submission Date: Click here to enter a date

Submission to: IPRO State: Louisiana Department of Health

#### 1. Principal MCO Contact Person

[PERSON RESPONSIBLE FOR COMPLETING THIS REPORT AND WHO CAN BE CONTACTED FOR QUESTIONS]

Carey Hotard Project Manager II, Quality Improvement 866-595-8133, ext. 85408 chotard@louisianahealthcareconnect.com

PIP proposal: Principal MCO Contact Signature Baseline Report: Principal MCO Contact Signature Interim Report: Principal MCO Contact Signature Final Report:

Date Date Date 10/10/19

#### 2. Additional Contact(s)

[PERSON(S) RESPONSIBLE IN THE EVENT THAT THE PRINCIPAL CONTACT PERSON IS UNAVAILABLE]

Joseph Tidwell Vice President, Quality Improvement 225-663-5764 jotidwell@louisianahealthconnect.com

Gwen Laury Director, Quality Improvement 225-201-8430 Gwendolyn.d.laury@louisianahealthconnect.com

### 3. External Collaborators (if applicable): N/A

## 4. For Final Reports Only: If Applicable, Summarize and Report All Changes in Methodology and/or Data Collection from Initial Proposal Submission:

As reported in the Interim Report, process measures under the High Risk Registry intervention and Enhancement of Case Management Services were changed due to the difficulties with data collection. The process measures that were originally submitted in the initial PIP Proposal included those around measuring the percentages of women on the High Risk Registry that received 17P injections and the percentage that were enrolled in Case Management services. These process measures showed excessive variability in the numbers, particularly with the denominators, which indicates the methodology for capturing data was not valid or reliable. New process measures were developed around these areas and were included in the interim report and in this final report.

#### 5. Attestation

#### Managed Care Plan Name: Louisiana Healthcare Connections Title of Project: Improving Prenatal and Postpartum Care to Reduce the Risk for Preterm Birth

#### Required Attestation signatures for PIP Proposal and PIP Final Report:

(1) Medical Director or Chief Medical Officer; (2) Quality Director or Vice President for Quality

The undersigned approve this PIP Proposal and assure involvement in the PIP throughout the course of the project.

Medical Director Signature Printed Name	Date
Quality Director Signature Printed Name	Date
IS Director Signature (when applicable) Printed Name	Date
CEO Signature Printed Nante	Date

The undersigned approve this FINAL PIP Report: Marino A Wallow, MD, MBA

Date 10/10/18

Dr. Marcus Wallace, Sr. Vice President, Medical Affairs

Joe Tidwell, Vice President, Quality Improvement

Date 10/10/18

Date

A mie Schlottman , Plan President and CEO

Date 10/10/18

Healthcare Effectiveness and Data Information Set (HEDIS®) is a registered trademark of the National Committee for Quality Assurance (NCQA).

## Abstract

The Abstract should be drafted for the Interim Report and finalized for the Final Report submission. Should not exceed 2 pages.

Provide an abstract of the PIP highlighting the project topic, rationale and aims, briefly describe the methodology and interventions, and summarize results and major conclusions of the project (refer to instructions in full report template or appendix).

#### **Project Topic/Rationale/Aims**

**Title of Project:** Improving Prenatal and Postpartum Care to Reduce the Risk for Preterm Birth **Rationale for Project:** The State of Louisiana's premature birth rate was 15.1% in 2013, and the State pledged to reduce the preterm birth rate by 8% in 2014 (March of Dimes Foundation, 2014). Further, the Department of Health and Hospitals of the State of Louisiana targets a 15% reduction in the statewide prematurity rate by 2017. Please refer to page 6 for more detailed information on the rationale for this project.

**Project Aims:** The Collaborative PIP aims to decrease the preterm birth rate by implementing a robust set of health plan, member and provider interventions to improve rates in various performance indicators. Please refer to page 7 for a detailed list of these indicators.

#### Methodology

Eligible Population: Women of child-bearing age who are enrolled in the Louisiana Medicaid program.

**Description of Annual Performance Indicators:** A total of 7 performance indicators have been selected. They are a combination of HEDIS and non-HEDIS measures. Please refer to page 9 for the complete list and a description of each.

#### Sampling Method: N/A

**Baseline and Re-measurement Periods:** Please see page 10 for the table of baseline and all subsequent remeasurement periods.

Data Collection Procedures: Data is collected through medical record reviews and claims.

#### Interventions

**Member Barriers Identified:** Lack of high-risk member relationship with provider, case management engagement, and awareness of appropriate treatment.

Interventions to address member barriers: Enhanced Case Management Services, Notification of Pregnancy

**Provider Barriers Identified:** Lack of provider knowledge of plan services such as case management and coordination, billing and coding for progesterone and contraception interventions

Interventions to address provider barriers: Provider Education, Notification of Pregnancy

#### Results

**Report Data for Annual Performance Indicators:** All data for the annual Performance Indicators can be found beginning on page 19.

#### Conclusions

**Interpret improvement in terms of whether or not Target Rates were met for annual performance indicators:** Overall, target rates for the annual performance indicators were not met, despite showing an increase in some areas. We show an increase in chlamydia testing in pregnant women but a decrease in syphilis testing. Rates around contraception remained stable. There was an increase in our 17P utilization rates and we exceeded the target rate of 17.5% in utilization in women between 16-24 weeks gestation.

**Indicate interventions that did and did not work in terms of quarterly intervention tracking measure trends:** When studying the process measure trends, it can be seen that our NOP submission rate has remained high. Although the overall rates have fluctuated a bit, our overall NOP submission rate remains over 50% of all known deliveries. One obstacle we face with NOPs is the form not being fully completed and/or legible, which can hinder CM outreach. Other measures that are showing an increase include our Case Management process measures. Outreach to high risk pregnant women has remained at an average of around 90%, however the last three quarters have all been over 96%. We have a Six Sigma project centered on Case Management engagement. These rates have also shown an increase over the last two quarters, with over a 10% increase in the last quarter alone. High NOP submissions coupled with an increase in case management engagement rates contributes to the plan being able to identify those women who are at high risk for a preterm birth which will result in more interventions being offered to prevent future preterm births.

**Study Design Limitations:** In an effort to obtain the most accurate data, we transitioned to an upgraded version of QSI (QSI-XL). During that transition, there were some issues with measure builds, however all issues have been corrected. All data for the Prematurity PIP performance indicators is collected administratively, which means we are dependent on providers coding claims accurately.

**Lessons Learned and Next Steps:** Next steps include continuing our efforts in this PIP for an additional year and also working with the Intervention Tracking Measure workgroup to focus on process measures that may be able to help us define interventions and process measures in a more real-time sense.

## 1. Project Topic/ Rationale and 2. Aim

Suggested length: 2 pages

### 1. Describe Project Topic and Rationale for Topic Selection

- Describe how PIP Topic addresses your member needs and why it is important to your members (e.g., disease prevalence stratified by demographic subgroups): Louisiana Healthcare Connections operates with a mission of providing better health at lower costs. As part of its dedication to the members it serves and in order to ensure compliance with the Louisiana Department of Health (LDH) requirement for Healthy Louisiana Plans, Louisiana Healthcare Connections, herein referred to as "the Plan", is working collaboratively with LDH and other MCOs on two performance improvement projects (PIPs). One of the two annual PIPs focuses on reducing preterm deliveries among its childbearing females. This measure includes reducing the preterm delivery rate. In order to determine the focus of this performance improvement project, the Plan began by reviewing the list of options provided by LDH to Healthy Louisiana Plan. A review of the membership as of May 20<sup>th</sup>, 2015 was conducted and analysis of the demographic information of its membership was completed. The Plan also reviewed historical data on the health outcomes and preventive health measures compliance amongst national and state residents. Finally, a review of best practices and recommendations from leading healthcare advisory groups was made to determine the best methods of increasing compliance and improving health outcomes.
- Describe current research support for topic (e.g., clinical guidelines/standards): The March of Dimes aims for a national premature birth rate no higher than 9.6% by 2020 (March of Dimes Foundation, 2014). Early prenatal care allows for timely identification and intervention for actionable risk factors. According to the American College of Obstetricians and Gynecologists, prior preterm birth is one of the strongest risk factors for preterm birth (ACOG, 2012a), and between 5 and 8% of preterm deliveries are attributable to maternal smoking (ACOG, 2010). There is strong evidence for effective interventions to minimize these risks, including pregnancy-tailored tobacco cessation counseling (ACOG, 2010) and progesterone therapy for prior spontaneous preterm birth (ACOG, 2008; Preconception Health Council of California, 2012). Untreated sexually transmitted infections (STI) have been associated with adverse birth outcomes such as preterm delivery (Rours et al, 2011) and stillbirth (USPSTF, 2009), and intrauterine and perinatally transmitted STIs can adversely affect pregnant women and their fetuses (CDC, 2010). The CDC recommends screening pregnant women for STI, including chlamydia trachomatis and syphilis, early in pregnancy, and screening for Neisseria gonorrhea for pregnant women at risk or living in areas with high prevalence (CDC, 2010). Further, rescreening for STI in the third trimester is recommended for women at high risk for infection. The U.S. Preventive Services Task Force recommends that all pregnant women should be screened for HIV infection as early in pregnancy as possible (Chou et al., 2012; Moyer and USPSTF, 2013). Developing strategies to minimize barriers to early initiation of prenatal care and evidence-based care such as tobacco cessation counseling, progesterone therapy and/or STI screening, referral and treatment, can potentially reduce risk for preterm birth. Risk factors for preterm birth can also be addressed in the postpartum period. For example, approximately 50%-60% of women who quit smoking during pregnancy relapse in the first year postpartum, and postpartum visits provide an opportunity to initiate interconception smoking cessation interventions (ACOG, 2010). The postpartum period is also an opportune time to address pregnancy intention and birth spacing. In light of evidence that birth to pregnancy (BTP) intervals of 18 months or less are associated with preterm delivery, the recommended interval before attempting the next pregnancy is at least 24 months (WHO, 2006; Sober and Schreiber, 2014). Long-acting reversible contraception (LARC) methods are the most effective reversible contraceptives, and immediate postpartum insertion may provide a safe and effective means to reduce unintended pregnancy among eligible women, including eligible adolescent mothers, who are at high risk for rapid, repeat pregnancy (ACOG, 2011; Sober and Schreiber, 2014; ACOG, 2012b). It should be

noted that although the inter-pregnancy postpartum visit affords opportunities to potentially reduce the likelihood of preterm birth and improve pregnancy outcomes, all of the Healthy Louisiana Plans scored below the HEDIS 2014 national Medicaid HMO 50th percentile for the measure of attendance at a postpartum visit.

Explain why there is opportunity for MCO improvement in this area: The State of Louisiana's premature birth rate was 15.1% in 2013, and the State pledged to reduce the preterm birth rate by 8% in 2014 (March of Dimes Foundation, 2014). Further, LDH targets a 15% reduction in the statewide prematurity rate by 2017. Healthy People 2020 specifically targets reductions in preterm births (<37 weeks gestational age) and very preterm births (<32 weeks gestational age) to 11.4% and 1.8%, respectively, and corresponding percentages in Louisiana (LA) are higher, at 12.4% and 2.3% (DHH-LA, 2014). Racial disparities are evident among the LA population. Across all LA regions, preterm birth rates are highest among the black subpopulation, with the highest rates in Region 7, i.e., 20.5% for preterm and 4.1% for very preterm births (DHH-LA, 2014). Disparities are also evident by type of insurance coverage. In Louisiana, 15.6% (95% CI=12.0-19.1) of publicly insured children were born premature, compared to 10.5% (95% CI=10.0-11.1) of privately insured children nationwide (NSCH, 2011/12). Among the LA subpopulation insured by Medicaid at preconception, the percentage with a prior preterm birth in 2008 was 16.7% (DHH-LA, 2008); this represents a susceptible subpopulation that may benefit from performance improvement project initiatives to improve prenatal, postpartum and inter-conception care. Early prenatal care is recommended by the Centers for Disease Control and Prevention (CDC) as a means for women to reduce the risk for preterm birth (CDC, 2014a), yet only two of the five Healthy Louisiana plans scored at or above the HEDIS 2014 national Medicaid HMO 50<sup>th</sup> percentile for the measure of early initiation of prenatal care, and none of the plans rates scored at the 95<sup>th</sup> percentile.

### 2. Aim Statement, Objectives and Goals

The Collaborative PIP aims to decrease the preterm birth rate by implementing a robust set of health plan, member and provider interventions to improve rates of the following performance indicators:

- 1. The percentage of women 15-45 years of age with evidence of a previous pre-term singleton birth event (<37 weeks completed gestation) who received one or more progesterone injections between the 16th and 21st week of gestation (also reported as in the PTB incentive measure).
- 2. The percentage of women aged 16 years and older who delivered a live birth and had at least one test for chlamydia during pregnancy.
- 3. The percentage of women who delivered a live birth and had at least one test for HIV during pregnancy.
- 4. The percentage of women who delivered a live birth and had at least one test for syphilis during pregnancy.
- 5. The percentage of postpartum women who:
  - a. Adopt use of a most effective FDA-approved method of contraception, i.e., (i) female sterilization or (ii) Long-Acting Reversible Contraception (LARC), i.e., contraceptive implants, or intrauterine devices of systems (IUD/IUS)
  - b. Adopt use of a moderately effective method of contraception, i.e., use of injectables, oral pills, patch, ring or diaphragm.
  - c. Adopt use of LARC during delivery hospitalization
  - d. Adopt use of LARC outpatient within 56 days postpartum
- 6. The percentage of women with a postpartum visit as per the HEDIS PPC postpartum measure

**Objectives:** Reduce the risk for preterm birth by implementing a robust set of member, provider and health plan interventions to address the following intervention strategies: (1) Notice of Pregnancy (NOP) provider to plan communication; (2) High Risk Registry Plan to provider communication; (3) Provider education (Medicaid 101); and (4) Prenatal Care Management Outreach and Engagement Program Targeted to High Risk Members.

#### Goal(s):

Each of the 9 performance indicators (1-6, above) should have its own unique goal. Enter a goal statement for each performance indicator, below:

1. The percentage of women 15-45 years of age with evidence of a previous pre-term singleton birth event (<37 weeks completed gestation) who received one or more progesterone injections between the 16th and 21st week of gestation (also as reported in the PTB incentive measure).

**Baseline to final measurement goal:** An improvement from the baseline 2.16% to 17.5% in the percentage of women 15-45 years of age with evidence of a previous pre-term singleton birth event (<37 weeks completed gestation) who received one or more progesterone injections between the 16th and 21st week of gestation.

2. The percentage of women aged 16 years and older who delivered a live birth and had at least one test for chlamydia during pregnancy.

**Baseline to final measurement goal:** An improvement from the baseline 70.29% to 87% in the percentage of women aged 16 years and older who delivered a live birth and had at least one test for chlamydia during pregnancy.

3. The percentage of women who delivered a live birth and had at least one test for HIV during pregnancy. **Baseline to final measurement goal:** An improvement from the baseline 5.95% to 32% in the percentage of women who delivered a live birth and had at least one test for HIV during pregnancy.

4. The percentage of women who delivered a live birth and had at least one test for syphilis during pregnancy. **Baseline to final measurement goal:** An improvement from the baseline 71.18% to 85% in the percentage of women who delivered a live birth and had at least one test for syphilis during pregnancy.

5. The percentage of postpartum women who:

a. Adopt use of a most effective FDA-approved method of contraception, i.e., (i) female sterilization or (ii) Long-Acting Reversible Contraception (LARC), i.e., contraceptive implants, or intrauterine devices of systems (IUD/IUS)

**Baseline to final measurement goal:** Adopt use of a most effective FDA-approved method of contraception, i.e., (i) female sterilization or (ii) Long-Acting Reversible Contraception (LARC), i.e., contraceptive implants, or intrauterine devices of systems (IUD/IUS) from a baseline of 19.56% to 30%.

b. Adopt use of a moderately effective method of contraception, i.e., use of injectables, oral pills, patch, ring or diaphragm.

**Baseline to final measurement goal:** Adopt use of a moderately effective method of contraception, i.e., use of injectable, oral pills, patch, ring or diaphragm from a baseline of 23.31% to 30%.

c. Adopt use of LARC during delivery hospitalization

**Baseline to final measurement goal:** Adopt use of a LARC during delivery hospitalization from a baseline of 1.90% to 30%.

d. Adopt use of LARC outpatient within 56 days postpartum

**Baseline to final measurement goal:** Adopt use of a LARC in an outpatient setting within 56 days postpartum from a baseline of 6.86% to 30%.

6. The percentage of women with a postpartum visit as per the HEDIS PPC postpartum measure **Baseline to final measurement goal:** An improvement in the percentage of women with a postpartum visit as per the HEDIS PPC Postpartum Measure per the baseline administrative rate of 45.96% to 55% and the baseline hybrid rate of 58.23% to 70%

#### **Performance Indicators**

Utilize the Prematurity PIP Performance Measures specifications referenced below for each performance indicator.

- 1. The percentage of women 15-45 years of age with evidence of a previous pre-term singleton birth event (<37 weeks completed gestation) who received one or more progesterone injections between the 16th and 21st week of gestation: 17P\_PIP\_Measure\_5\_17\_16\_clean.docx
- 2. The percentage of women 15-45 years of age with evidence of a previous pre-term singleton birth event (<37 weeks completed gestation) who received one or more progesterone injections between the 16th and 24th week of gestation (PTB incentive measure): LA Performance Measure Submission Guide
- 3. The percentage of women aged 16 years and older who delivered a live birth and had at least one test for chlamydia during pregnancy: chlamydia\_screening\_7\_25\_15.docx
- 4. The percentage of women who delivered a live birth and had at least one test for HIV during pregnancy: HIV\_and\_syphilis\_screening\_10\_27\_15.docx
- 5. The percentage of women who delivered a live birth and had at least one test for syphilis during pregnancy: HIV\_and\_syphilis\_screening\_10\_27\_15.docx.
- 6. The percentage of postpartum women who: (LA\_Prematurity\_PIP\_contraceptive\_measure\_revised\_5\_17\_16clean.docx; group to discuss use of CMS Adult Core Set measure CCP-AD Contraceptive Care Postpartum Women age 21-44 years and CMS Child Core Set measure CCP-CH Contraceptive Care Postpartum Women age 15-20 years as next step for PIP extension measurement year 2018):
  - a. Adopt use of a most effective FDA-approved method of contraception, i.e., (i) female sterilization or (ii) Long-Acting Reversible Contraception (LARC), i.e., contraceptive implants, or intrauterine devices of systems (IUD/IUS)
  - b. Adopt use of a moderately effective method of contraception, i.e., use of injectables, oral pills, patch, ring or diaphragm
  - c. Adopt use of LARC during delivery hospitalization
  - d. Adopt use of LARC outpatient within 56 days postpartum
- 7. The percentage of women with a postpartum visit as per the HEDIS PPC postpartum measure

### **Data Collection and Analysis Procedures**

Is the entire eligible population being targeted by PIP interventions? Yes.

If sampling was employed: Describe sampling methodology: N/A Sample Size and Justification: N/A

#### Data Collection:

Data will be collected using the Centene-level corporate Quality Spectrum Insight (QSI-XL) database. All numerators and denominators for the annual performance measures come from this source. Data governance is under the oversight of the Quality Department of Louisiana Healthcare Connections in conjunction with Centene Corporation using the QSI-XL database. Data from 2012 through October 31, 2015 is retrospective. Data from November 2015 through present will be prospective which coincides with all active interventions or treatments being applied. Audits of clinical data or medical records will be performed if needed to corroborate the findings from the QSI analysis. Therefore, hybrid methodology may be employed if needed to scrub the data and ensure data reliability and validity.

Data stratification occurs pending results of initial analysis to determine if there are potentially different populations or subgroups in the overall data. For this PIP we are utilizing data from the high risk registry and LEERS reports supplied by LDH. We are also utilizing QSI-XL for member and provider profile, HEDIS metrics report, Louisiana Healthcare Connections SharePoint for documentation, trending and tracking purposes, and NOP reports supplied by Centene Corporation. LHCC ensures the validity and reliability of the data through weekly meetings between plan data analytics and corporate analytics. In addition, reports go through test run for reliability.

#### Validity and Reliability

(For definitions, refer to Glossary of PIP Terms in HEALTHY\_LOUISIANA\_PIP\_TEMPLATE\_w\_example):

Data is validated by our Quality Improvement Abstractors, the HEDIS team, and our Analytics Department. All Quality Improvement Abstractors are provided training and must pass subsequent testing. Abstractors are also audited on a quarterly basis. We validate data by having multiple analysts run same data for a volume check and dig further if there is a discrepancy.

#### Data Analysis:

Data is compared to previous year's data when available, denominators and numerators will be checked for inclusion of all eligible populations and any discrepancies are investigated. Data is compared to all sources and histories available in an effort to produce the most valid answer possible.

#### **Timeline**

Event	Timeframe
Baseline Measurement Period	November 6, 2104 – November 5, 2015
Interim Measurement Period	November 6, 2015 – November 5, 2016
Submission of Interim Report	June 30, 2017
Final Re-measurement Period	November 6, 2016 – November 5, 2017
Intervention Implementation	November 6, 2015 – November 5, 2017
Analysis of Project Data	Ongoing
Submission of Final Report	June 30, 2018
Extension Measurement Period	November, 2017- November 5, 2018
Submission of Extended PIP Report	June 30, 2019

## 4. Barriers and 5. Interventions

This section describes the barriers identified and the related interventions planned to overcome those barriers in order to achieve improvement.

## Populate the tables below with relevant information, based upon instructions in the footnotes.

Add rows as needed.

Table of Barriers Identified and the Interventions Designed to Overcome Each Barrier.

Description of Barrier <sup>2</sup>	Method and Source of Barrier Identificatio n <sup>3</sup>	Number of Interven tion	Description of Intervention Designed to Overcome Barrier <sup>4</sup>	Interventi on Timefram e <sup>5</sup>
Lack of accurate and complete data to identify high risk pregnant members	Plan tracking of NOPs	1	Notification of Pregnancy (NOP)	Planned Start: 01/01/2016 Actual Start: 01/01/2016 Date Revised:
Lack of high risk member and OB engagement	Interactions with members and providers; member feedback through experience surveys	2	Medicaid 101	Planned Start: 01/01/2016 Actual Start: 01/01/2016 Date Revised:
Lack of high risk member awareness of appropriate treatment and engagement with CM	Plan tracking of CM engagement	3	Enhancement of Case Management Services	Planned Start: 01/01/2016 Actual Start: 01/01/2016 Date Revised:
Lack of accurate identification of high risk members with history of preterm birth	Plan tracking of CM data	4	High Risk Registry	Planned Start: 01/01/2016 Actual Start: 01/01/2016 Date Revised: 07/01/2017

2,3,4,5: See PIP HEALTHY\_LOUISIANA\_PIP\_TEMPLATE\_w\_examples for examples and additional guidance.

## Monitoring Table YEAR 1: Quarterly Reporting of Rates for Intervention Tracking Measures, with corresponding intervention numbers.

Add rows as ne	eded.
----------------	-------

Number of	Description of	Q1	Q2	Q3	Q4
Intervention	Intervention Tracking	2016	2016	2016	2016
	Measures <sup>6</sup>	2010	2010	2010	2010
1	Percentage of deliveries	Numerator:	Numerator:	Numerator:	Numerator:
	that plan received an NOP	1372	1383	1762	1708
	Num: Count of births with	Denominator:	Denominator:	Denominator:	Denominator:
	NOP 8 months prior to	2700	2742	3392	3169
	Delivery	Rate: 50.81%	Rate: 50.44%	Rate: 51.95%	Rate: 52.90%
	<b>Denom</b> : Total Number of				
4	deliveries				
1	Percentage of member-	Numerator:	Numerator:	Numerator:	Numerator:
	submitted NOPs <b>Num</b> : Number of NOP	1658 Denominatori	1659 Denominatori	1506 Denominatori	1418 Deneminatori
	forms submitted to LHCC	Denominator: 2921	Denominator: 2786	Denominator: 2992	Denominator: 2734
	from members	Rate: 56.76%	Rate: 59.55%	Rate: 50.33%	Rate51.87%
	<b>Denom</b> : Total number of	Tale: 50.7070	Nate: 09.0070	Nate: 50.5570	Tale51.0770
	NOP forms submitted to				
	LHCC				
1	Percentage of provider-	Numerator:	Numerator:	Numerator:	Numerator:
	submitted NOPs	1263	1127	1486	1316
	Num: Number of NOP	Denominator:	Denominator:	Denominator:	Denominator:
	forms submitted to LHCC	2921	2786	2992	2734
	from providers	Rate: 43.24%	Rate: 40.52%	Rate: 49.67%	Rate: 48.13%
	Denom: Total number of				
	NOP forms submitted to				
2	LHCC Dereentage of academic	Numerator: 3	Numerator: 3	Numerator: 9	Numerator: 9
Ζ	Percentage of academic detailing visits completed	Denominator:	Denominator:	Denominator:	Denominator:
	during the year. * <i>This is a</i>	11	11	11	11
	cumulative measure	Rate: 27.27%	Rate: 27.27%	Rate: 81.82%	Rate: 81.82%
	throughout the year.			110101 0 1102 /0	
	Num: Number of OBGYN				The remaining
	visits completed by the				two visits were
	Medical Director YTD				completed Q1
	Denom: Total number of				2017
	OBGYN visits planned				
	during the year				
2	Percentage of OB/GYN	Numerator:	Numerator:	Numerator:	Numerator: 131
	visits completed by the Provider Network team with	Enter #	Enter #	197 Denominatori	Denominator:
	"Better OB/GYN	Denominator:	Denominator:	Denominator: 231	231 Rate: 56.71%
	Resources" material	Enter #	Enter #	Rate: 85.28%	Nale. 30.7170
	presented	Rate: Enter	Rate: Enter	Nate: 00.2070	
	Num: Total number of	results of	results of		
	OB/GYN provider visits	num÷denom	num÷denom		
	completed with "Better	Macaura sat	Measure not		
	OB/GYN Resources"	Measure not	started until Q3		
	presented	started until Q3 2016	2016		
	Denom: Total number of	2010	2010		
	OB/GYN provider visits				
	planned to present "Better				
	OB/GYN Resources"				

3	Percentage of women determined to have a need for 17P that began regimen in the given quarter <b>Num:</b> The total # of members who started their 17P regimen in the given quarter <b>Denom:</b> The total number of deliveries determined to have a need for 17P (Number of Deliveries * % multiparous (.65) * preterm delivery rate (.123) * % spontaneous (.75))	Numerator: 61 Denominator: 163.56 Rate: 37.29%	Numerator: 81 Denominator: 167.58 Rate: 48.34%	Numerator: 90 Denominator: 207 Rate: 43.48%	Numerator: 89 Denominator: 193.26 Rate: 46.05%
3	Percentage of high risk pregnant members that receive CM outreach within 7 days of notification <b>Num</b> : Number of high risk pregnant members that receive CM outreach within 7 days of notification to the plan <b>Denom</b> : Total number of high risk pregnant members that plan has received notification on	Numerator: 219 Denominator: 255 Rate: 88.88%	Numerator: 216 Denominator: 250 Rate: 86.40%	Numerator: 258 Denominator: 300 Rate: 86.00%	Numerator: 219 Denominator: 247 Rate88.66%
3	Percentage of members who were enrolled within 30 days of NOP <b>Num</b> : Count of high risk pregnant members that were enrolled in CM within 30 days of notification with a plan of care developed collaboratively between the member and case manager <b>Denom</b> : Count of high risk pregnant members eligible for CM enrollment within 30 days	Numerator: Enter # Denominator: Enter # Rate: Enter results of num÷denom Measure started Q2 2016	Numerator: 86 Denominator: 462 Rate: 18.61%	Numerator: 105 Denominator: 443 Rate: 23.70%	Numerator: 97 Denominator: 363 Rate: 26.72%
3	Percentage of members who were enrolled within 60 days of NOP <b>Num</b> : Count of high risk pregnant members that were enrolled in CM within 60 days of notification with a plan of care developed collaboratively between the member and case manager <b>Denom</b> : Count of high risk pregnant members eligible for CM enrollment within 60 days	Numerator: Enter # Denominator: Enter # Rate: Enter results of num÷denom Measure started Q2 2016	Numerator: 99 Denominator: 451 Rate: 21.95%	Numerator: 109 Denominator: 434 Rate: 25.12%	Numerator: 143 Denominator: 361 Rate: 39.61%

4	Percentage of members on	Numerator:	Numerator: 45	Numerator: 32	Numerator: 42
4	the High Risk Registry that	Enter #	16	19	42
	were identified as currently	Denominator:	Denominator:	Denominator:	Denominator:
	being pregnant and	Enter #	1837	1691	1379
	outreached and enrolled in		Rate: 2.45%	Rate: 1.89%	Rate: 2.05%
	CM	Rate: Enter	0.87%	1.12%	3.05%
	Num: #1 Total number of	results of	0.0770	1.1270	0.0070
	high risk, pregnant	num÷denom			After review of
	members outreached and				data, it was felt
	#2 enrolled in CM	Measure			that these
	<b>Denom</b> : Total number of	started Q2 2016			numbers were
	members listed on the high				not able to be
	risk pregnancy file				pulled
	1 3 3				accurately.
4	Percentage of members on	Numerator:	Numerator: 2	Numerator: 0	Numerator: 0
	the HRR who were	Enter #	1	0	0
	outreached between 16-24	Denominator:	Denominator:	Denominator:	Denominator:
	weeks gestation for	Enter #	1837	1691	1379
	possible 17P	Rate: Enter	Rate: 0.11%	Rate: 0.00%	Rate: 0.00%
	Num: #1 Total number of	results of	0.05%	0.00%	0.00%
	high risk, pregnant	num÷denom			
	members outreached	num . ucnom			After review of
	between wks 16-24 and #2	Measure			data, it was felt
	enrolled in CM between	started Q2 2016			that these
	wks 16-24				numbers were
	Denom: Total number of				not able to be
	members listed on the high				pulled
	risk pregnancy file				accurately.
4	Percentage of members on	Numerator:	Numerator: 9	Numerator: 5	Numerator: 6
	the HRR who started 17P	Enter #	Denominator:	Denominator:	Denominator:
	injections in the given	Denominator:	1837	1691	1379
	quarter	Enter #	Rate: 0.49%	Rate: 0.30%	Rate: 0.44%
	Num: Total number of high	Rate: Enter			A.C
	risk pregnancy members	results of			After review of
	started on the	num÷denom			data, it was felt
	hydroprogesterone				that these
	injections	Measure			numbers were
	<b>Denom</b> : Total number of	started Q2 2016			not able to be
	members listed on the high				pulled
					accurately.

6: See PIP HEALTHY\_LOUISIANA\_PIP\_TEMPLATE\_w\_examples for examples and additional guidance.

### Monitoring Table YEAR 2: Quarterly Reporting of Rates for Intervention Tracking Measures, with corresponding intervention numbers. Add rows as needed.

Number of Intervention	Description of Intervention Tracking Measures <sup>6</sup>	Q1 2017	Q2 2017	Q3 2017	Q4 2017
1	Percentage of deliveries that plan received an NOP <b>Num</b> : Count of births with NOP 8 months prior to Delivery <b>Denom</b> : Total Number of deliveries	Numerator: 1561 Denominator: 2935 Rate: 53.19%	Numerator: 1484 Denominator: 2831 Rate: 52.42%	Numerator: 1847 Denominator: 3231 Rate: 57.17%	Numerator: 1729 Denominator: 3107 Rate: 55.65%

1	Percentage of member- submitted NOPs	Numerator: 1433	Numerator: 1692	Numerator: 1336	Numerator: 1484
	Num: Number of NOP forms submitted to LHCC	Denominator: 2939	Denominator: 2756	Denominator: 2542	Denominator: 2591
	from members	Rate: 48.76%	Rate: 61.39%	Rate: 52.56%	Rate57.28%
	<b>Denom</b> : Total number of				
	NOP forms submitted to LHCC				
1	Percentage of provider-	Numerator:	Numerator:	Numerator:	Numerator:
	submitted NOPs <b>Num</b> : Number of NOP	1506 Denominator:	1064 Denominator:	1206 Denominator:	1107 Denominator:
	forms submitted to LHCC	2939	2756	2542	2591
	from providers Denom: Total number of	Rate: 51.24%	Rate: 38.61%	Rate: 47.44%	Rate: 42.73%
	NOP forms submitted to				
	LHCC				
2	Percentage of academic	Numerator: 3	Numerator: 4	Numerator: 15 Denominator:	Numerator: 22
	detailing visits completed during the year. <i>*This is a</i>	Denominator: 20	Denominator: 20	20	Denominator: 22
	cumulative measure	Rate: 15.00%	Rate: 20.00%	Rate: 75.00%	Rate: 100.00%
	throughout the year.				
	Num: Number of OBGYN visits completed by the				Two visits were added on
	Medical Director YTD				towards end of
	<b>Denom</b> : Total number of				year.
	OBGYN visits planned during the year				
2	Percentage of OB/GYN	Numerator: 0	Numerator: 0	Numerator: 24	Numerator: 271
	visits completed by the	Denominator: 0	Denominator: 0	Denominator:	Denominator:
	Provider Network team with "Better OB/GYN	Rate: 0.00%	Rate: 0.00%	385 Rate: 6.23%	299 Rate: 90.64%
	Resources" material	OB outreach			
	presented	scheduled for			
	Num: Total number of OB/GYN provider visits	Q4 2017			
	completed with "Better				
	OB/GYN Resources"				
	presented Denom: Total number of				
	OB/GYN provider visits				
	planned to present "Better				
2	OB/GYN Resources" Percentage of PCP visits	Numerator: 142	Numerator:	Numerator:	Numerator: 260
-	completed by the Provider	Denominator:	101	266	Denominator:
	Network team with	1364 Data: 40.44%	Denominator:	Denominator:	1315 Data: 40.77%
	"Preventive Care Incentives" material	Rate: 10.41%	1365 Rate: 6.52%	1348 Rate: 19.29%	Rate: 19.77%
	presented		1440. 0.027	10.2070	
	Num: Total number of PCP				
	provider visits completed with "Preventive Care				
	Incentives" presented				
	<b>Denom</b> : Total number of				
	PCP provider visits planned to present "Preventive Care				
	Incentives"				
	Additional PCP visits were				
	held that included preterm birth education but could				
	not be verified and were				
	taken out of the				
	denominator				

3	Percentage of women	Numerator: 96	Numerator: 81	Numerator:	Numerator: 73
5	Percentage of women determined to have a need	Denominator: 96	Denominator: 81	Numerator: 100	Denominator: 73
	for 17P that began regimen	178.56	172.26	Denominator:	189.18
	in the given quarter	Rate: 53.76%	Rate: 48.34%	207	Rate: 38.62%
	<b>Num:</b> The total # of	1410. 00.7070	Tate: +0.0+70	Rate: 43.48%	Tate: 00.0270
	members who started their			140.40.4070	
	17P regimen in the given				
	quarter				
	<b>Denom</b> : The total number				
	of deliveries determined to				
	have a need for 17P				
	(Number of Deliveries * %				
	, multiparous (.65) * preterm				
	delivery rate (.123) * %				
	spontaneous (.75))				
3	Percentage of high risk	Numerator: 231	Numerator:	Numerator:	Numerator: 284
	pregnant members that	Denominator:	249	256	Denominator:
	receive CM outreach within	308	Denominator:	Denominator:	294
	7 days of notification	Rate: 75.00%	278	261	Rate: 96.60%
	Num: Number of high risk		Rate: 89.57%	Rate: 98.08%	
	pregnant members that				
	receive CM outreach within				
	7 days of notification to the				
	plan				
	Denom: Total number of				
	high risk pregnant members				
	that plan has received				
	notification on				
3	Percentage of members	Numerator: 97	Numerator:	Numerator: 69	Numerator: 85
	who were enrolled within 30	Denominator:	121	Denominator:	Denominator:
	days of NOP	363 Dete: 00 70	Denominator:	404 Dete: 47.00%	463
	Num: Count of high risk	Rate: 26.72	474 Dete: 20.05%	Rate: 17.08%	Rate: 18.36%
	pregnant members that were enrolled in CM within		Rate: 26.05%		
	30 days of notification with				
	a plan of care developed				
	collaboratively between the				
	member and case manager				
	<b>Denom</b> : Count of high risk				
	pregnant members eligible				
	for CM enrollment within 30				
	days				
3	Percentage of members	Numerator: 70	Numerator:	Numerator: 59	Numerator: 90
	who were enrolled within 60	Denominator:	127	Denominator:	Denominator:
	days of NOP	215	Denominator:	354	428
	Num: Count of high risk	Rate: 32.56%	464	Rate: 16.67%	Rate: 19.65%
	pregnant members that		Rate: 27.47%		
	were enrolled in CM within				
	60 days of notification with				
	a plan of care developed				
	collaboratively between the				
	member and case manager				
	Denom: Count of high risk				
	pregnant members eligible				
	for CM enrollment within 60				
1	days				

6: See PIP HEALTHY\_LOUISIANA\_PIP\_TEMPLATE\_w\_examples for examples and additional guidance.

Number of	Description of	Q1	Q2	Q3	Q4
Intervention	Intervention Tracking Measures <sup>6</sup>	2018	2018	2018	2018
1	Percentage of deliveries	Numerator:	Numerator:	Numerator:	Numerator:
	that plan received an NOP	1594	Enter #	Enter #	Enter #
	Num: Count of births with	Denominator:	Denominator:	Denominator:	Denominator:
	NOP 8 months prior to	2983 Rate: 53.44%	Enter #	Enter #	Enter #
	Delivery <b>Denom</b> : Total Number of	Rate. 55.44%	Rate: Enter	Rate: Enter	Rate: Enter
	deliveries		results of	results of	results of
			num÷denom	num÷denom	num÷denom
1	Percentage of member-	Numerator:	Numerator:	Numerator:	Numerator:
	submitted NOPs	1403	Enter #	Enter #	Enter #
	Num: Number of NOP forms submitted to LHCC	Denominator: 2500	Denominator:	Denominator:	Denominator:
	from members	Rate: 56.12%	Enter #	Enter #	Enter #
	<b>Denom</b> : Total number of	Trate: 00.1270	Rate: Enter	Rate: Enter	RateEnter
	NOP forms submitted to		results of	results of	results of
	LHCC		num÷denom	num÷denom	num÷denom
1	Percentage of provider-	Numerator:	Numerator:	Numerator:	Numerator:
	submitted NOPs	1097	Enter #	Enter #	Enter #
	Num: Number of NOP	Denominator:	Denominator:	Denominator:	Denominator:
	forms submitted to LHCC	2500	Enter #	Enter #	Enter #
D N	from providers	Rate: 43.88%	Rate: Enter	Rate: Enter	Rate: Enter
	<b>Denom</b> : Total number of		results of	results of	results of
	NOP forms submitted to LHCC		num÷denom	num÷denom	num÷denom
2	Percentage of academic	Numerator: 0	Numerator:	Numerator:	Numerator:
	detailing visits completed	Denominator:	Enter #	Enter #	Enter #
	during the year. <i>*This is a</i>	10	Denominator:	Denominator:	Denominator:
	cumulative measure	Rate: 0.00%	Enter #	Enter #	Enter #
	throughout the year.		Rate: Enter	Rate: Enter	Rate: Enter
	Num: Number of OBGYN		results of	results of	results of
	visits completed by the Medical Director YTD		num÷denom	num÷denom	num÷denom
	<b>Denom</b> : Total number of				
	OBGYN visits planned				
	during the year				
2	Percentage of OB/GYN	Numerator: 35	Numerator:	Numerator:	Numerator:
	visits completed by the	Denominator:	Enter #	Enter #	Enter #
	Provider Network team with	239	Denominator:	Denominator:	Denominator:
	"Better OB/GYN	Rate: 12.11%	Enter #	Enter #	Enter #
	Resources" material		Rate: Enter	Rate: Enter	Rate: Enter
	presented <b>Num:</b> Total number of		results of	results of	results of
	OB/GYN provider visits		num÷denom	num÷denom	num÷denom
	completed with "Better				
	OB/GYN Resources"				
	presented				
	<b>Denom</b> : Total number of				
	OB/GYN provider visits				
	planned to present "Better				
	OB/GYN Resources"				

2	Porcontago of DCD visite	Numerator: 188	Numerator:	Numorator	Numerator
2	Percentage of PCP visits completed by the Provider	Denominator: 188	Numerator: Enter #	Numerator: Enter #	Numerator: Enter #
	Network team with	1371	Denominator:	Denominator:	Denominator:
	"Preventive Care	Rate: 13.71%	Enter #	Enter #	Enter #
	Incentives" material		Rate: Enter	Rate: Enter	Rate: Enter
	presented				
	Num: Total number of PCP		results of	results of	results of
	provider visits completed		num÷denom	num÷denom	num÷denom
	with "Preventive Care				
	Incentives" presented				
	Denom: Total number of				
	PCP provider visits planned				
	to present "Preventive Care				
	Incentives"				
	Additional PCP visits were				
	held that included preterm				
	birth education but could				
	not be verified and were				
	taken out of the				
3	denominator Percentage of women	Numerator: 88	Numerator:	Numerator:	Numerator:
5	determined to have a need	Denominator:	Enter #	Enter #	Enter #
	for 17P that began regimen	181.62	Denominator:	Denominator:	Denominator:
	in the given quarter	Rate: 48.45%	Enter #	Enter #	Enter #
	<b>Num:</b> The total # of	1440. 10.1070	Rate: Enter	Rate: Enter	Rate: Enter
	members who started their		results of	results of	results of
	17P regimen in the given		num÷denom		
	quarter		nuni-aenom	num÷denom	num÷denom
	Denom: The total number				
	of deliveries determined to				
	have a need for 17P				
	(Number of Deliveries * %				
	multiparous (.65) * preterm				
	delivery rate (.123) * %				
3	spontaneous (.75)) Percentage of high risk	Numerator: 258	Numerator:	Numerator:	Numerator:
0	pregnant members that	Denominator:	Enter #	Enter #	Enter #
	receive CM outreach within	266	Denominator:	Denominator:	Denominator:
	7 days of notification	Rate: 96.99%	Enter #	Enter #	Enter #
	Num: Number of high risk		Rate: Enter	Rate: Enter	Rate: Enter
	pregnant members that		results of	results of	results of
	receive CM outreach within		num÷denom	num÷denom	num÷denom
	7 days of notification to the				
	plan				
	<b>Denom</b> : Total number of				
	high risk pregnant members				
	that plan has received notification on				
3	Percentage of members	Numerator: 120	Numerator:	Numerator:	Numerator:
	who were enrolled within 30	Denominator:	Enter #	Enter #	Enter #
	days of NOP	400	Denominator:	Denominator:	Denominator:
	Num: Count of high risk	Rate: 30.50%	Enter #	Enter #	Enter #
	pregnant members that		Rate: Enter	Rate: Enter	Rate: Enter
	were enrolled in CM within		results of	results of	results of
	30 days of notification with		num÷denom	num÷denom	num÷denom
	a plan of care developed				
	collaboratively between the				
	member and case manager				
	<b>Denom</b> : Count of high risk				
	pregnant members eligible for CM enrollment within 30				
	days				

3	Percentage of members	Numerator: 100	Numerator:	Numerator:	Numerator:
	who were enrolled within 60	Denominator:	Enter #	Enter #	Enter #
	days of NOP	324	Denominator:	Denominator:	Denominator:
	Num: Count of high risk	Rate: 30.86%	Enter #	Enter #	Enter #
	pregnant members that		Rate: Enter	Rate: Enter	Rate: Enter
	were enrolled in CM within		results of	results of	results of
	60 days of notification with a plan of care developed		num÷denom	num÷denom	num÷denom
	collaboratively between the member and case manager				
	Denom: Count of high risk				
	pregnant members eligible for CM enrollment within 60				
	days				

## 6. Results

The results section should present project findings related to performance indicators. Indicate target rates and rationale, e.g., next Quality Compass percentile. Accompanying narrative should describe, but *not* interpret the results in this section.

OPTIONAL: Additional tables, graphs, and bar charts can be an effective means of displaying data that are unique to your PIP in a concise way for the reader. If you choose to present additional data, include only data that you used to inform barrier analysis, development and refinement of interventions, and/or analysis of PIP performance.

Performance Indicator	Administrative (A) or Hybrid (H) Measure?	Baseline Period 2015	Interim Period 2016	Final Period 2017	Final Goal/Target Rate
Indicator #1 The percentage of women 15-45 years of age with evidence of a previous pre- term singleton birth event (<37 weeks completed gestation) who received one or more progesterone injections between the 16th and 21st week of gestation.	A	Eligible Population = 416 Exclusions= 0 If "H", Sample size = Enter # Numerator = 9 Denominator = 416 Rate = 2.16%	Eligible Population = 956 Exclusions= 0 If "H", Sample size = Enter # Numerator = 18 Denominator = 956 Rate = 1.88%	Eligible Population = 770 Exclusions= 0 If "H", Sample size = Enter # Numerator = 122 Denominator = 770 Rate = 15.84%	Target Rate: 17.5% Rationale: Plan set achievable yet bold goal
Indicator #2 The percentage of women 15-45 years of age with evidence of a previous pre- term singleton birth event (<37 weeks completed gestation) who received one or more progesterone injections between the 16th and 24th	A	Eligible Population = 1066 Exclusions= Enter # If "H", Sample size = Enter # Numerator = 145 Denominator = 1066 Rate = 13.60%	Eligible Population = 956 Exclusions= 0 If "H", Sample size = Enter # Numerator = 92 Denominator = 956 Rate = 9.62%	Eligible Population = 770 Exclusions= 0 If "H", Sample size = Enter # Numerator = 139 Denominator = 770 Rate = 18.05%	Target Rate: 17.5% Rationale: Plan set achievable yet bold goal

### Poculto Toblo

	*Mothod did not			
٨		Fligible	Fligible	Target Date
A				Target Rate: 87%
				Rationale:
				Plan set
				achievable yet
				bold goal
				bold godi
	Rate = 70.29%	Rate = 84.12%	Rate = 85.71%	
Α	Eligible	Eligible	Eligible	Target Rate:
	Population =	Population =	Population =	85%
	10306	11865	12085	Rationale:
	Exclusions= 0	Exclusions= 0	Exclusions= 0	Plan set
	If "H", Sample	lf "H", Sample	If "H", Sample	achievable yet
				bold goal
	• • • •			
	10306	11865	12085	
	Rate = 62.56%	Rate = 78.80%	Rate = 75.83%	
А				Target Rate:
	Population =	Population =	Population =	85%
	. 10306	. 11865	. 12065	Rationale:
	Exclusions= 0	Exclusions= 0	Exclusions= 0	Plan set
	If "H", Sample	If "H", Sample	If "H", Sample	achievable yet
	size = Enter #	size = Enter #	size = Enter #	bold goal
			Numerator =	
	10306	11865	12065	
	Rate = 71,28%	Rate = 82.81	Rate = 77.67%	
Α				Target Rate:
				30%
	9280		10941	Rationale:
	Exclusions= 0	Exclusions= 0	Exclusions= 0	Plan set
	lf "H", Sample	If "H", Sample	If "H", Sample	achievable yet
	size = Enter #	size = Enter #	size = Enter #	bold goal
	Numerator =	Numerator =	Numerator =	-
	795	1124	1047	
			<b>D</b>	
	Denominator =	Denominator =	Denominator =	
	Denominator = 9280	Denominator = 10456	Denominator = 10941	
		Population = 10420Exclusions = 0 If "H", Sample size = Enter # Numerator = 7324Numerator = 7324Denominator = 10420Rate = 70.29%AEligible Population = 10306Exclusions = 0 If "H", Sample size = Enter # Numerator = 	exist during BaselineAEligible Population = 10420 10076Exclusions=0 10420 10076Exclusions=0 If "H", Sample size = Enter # Numerator = 17324 Numerator = 10420Exclusions=0 If "H", Sample size = Enter # Numerator = 10420AEligible Population = 10420Denominator = 10076Rate = 70.29% Rate = 84.12%AEligible Population = 10306 If "H", Sample size = Enter # Numerator = Numerator = 10306 If "H", Sample size = Enter # Numerator = Numerator = Numerator = 10306 If "H", Sample size = Enter # Numerator = Numerator = 10306 It865AEligible Population = 10306 If "H", Sample size = Enter # Numerator = 10306 It865AEligible Population = 10306 It865AEligible Population = 10306 It865AEligible Population = 10306 It865AEligible Population = 10306 It6 "H", Sample size = Enter # Numerator = 7346 Pas25 Denominator = 10306 It865AEligible Population = 10306 It6 "H", Sample size = Enter # Numerator = 9280 10456AEligible Population = 10306 It6 "H", Sample size = Enter # Numerator = 9280 10456AEligible Population = 10456AEligible Population = 10456AEligible Population = 10456AEligible Population = 10456AEligible Population = 10456AEligible Population = 10456AEl	exist during BaselineAEligible Population = 10420Eligible Population = 10420Eligible Population = 10420AExclusions = 0 If "H", Sample size = Enter # Numerator = 1724FH", Sample size = Enter # Numerator = Numerator = 10420Exclusions=0 If "H", Sample size = Enter # Numerator = Numerator = 10420AEligible Population = 10420Denominator = 10076Denominator = 10642AEligible Population = 10306Eigible Population = Population = Numerator

Indicator #6b	A	Eligible	Eligible	Eligible	Target Rate:
The percentage of		Population =	Population =	Population =	30%
women who adopt		9280	10456	10941	Rationale:
use of a moderately		Exclusions= 0	Exclusions= 0	Exclusions= 0	Plan set
effective FDA-		If "H", Sample	If "H", Sample	If "H", Sample	achievable yet
approved method of		size = Enter #	size = Enter #	size = Enter #	bold goal
contraception		Numerator =	Numerator =	Numerator =	0
contraception		2195	2275	2396	
		Denominator =	Denominator =	Denominator =	
		9280	10456	10941	
		5200	10430	10341	
		Rate = 23.65%	Rate = 21.76%	Rate = 21.90%	
Indicator #6c	А	Eligible	Eligible	Eligible	Target Rate:
The percentage of		Population =	Population =	Population =	30%
women who adopt		9259	10456	10941	Rationale:
use of LARC during		Exclusions= 0	Exclusions= 0	Exclusions= 0	Plan set
delivery		If "H", Sample	If "H", Sample	If "H", Sample	achievable yet
hospitalization		size = Enter #	size = Enter #	size = Enter #	bold goal
nospitalization		Numerator =	Numerator = 191	Numerator = 170	
		176	Denominator =	Denominator =	
		Denominator =	10456	10941	
		9259	10400	10041	
		92.09	Rate = 1.83%	Rate = 1.55%	
		Rate = 1.90%	Nale - 1.0370	Rale - 1.55%	
lundia atau #Cal	A		Elizible	Elizible	Tarrat Data
Indicator #6d	A	Eligible	Eligible	Eligible	Target Rate:
The percentage of		Population =	Population =	Population =	30%
women who adopt		9259	10456	10941	Rationale:
use of LARC		Exclusions= 0	Exclusions= 0	Exclusions= 0	Plan set
outpatient 56 days		If "H", Sample	If "H", Sample	If "H", Sample	achievable yet
postpartum		size = Enter #	size = Enter #	size = Enter #	bold goal
		Numerator =	Numerator = 933	Numerator = 877	
		635	Denominator =	Denominator =	
		Denominator =	10456	10941	
		9259			
			Rate = 8.92%	Rate = 8.02%	
		Rate = 6.86%			
Indicator #7	Н	Eligible	Eligible	Eligible	Target Rate: 70%
The percentage of		Population = 419	Population = 404	Population = 380	0
women with a		Exclusions= 0	Exclusions= 0	Exclusions= 0	Rationale:
postpartum visit as		If "H", Sample	If "H", Sample	If "H", Sample	Plan set
per the HEDIS PPC		size = 419	size = 404	size = 380	achievable yet
-		Numerator =	Numerator = $262$	Numerator = $241$	bold goal
postpartum measure		244	Denominator =	Denominator =	bolu yoal
		Denominator =	404	380	
		419		D.1. 00.4004	
			Rate = 64.85%	Rate = 63.42%	
		Rate = 58.23%			

# 7. Discussion

The discussion section is for explanation and interpretation of the results. Please draft a preliminary explanation and interpretation of results, limitations and member participation for the Interim Report, then update, integrate and comprehensively interpret all findings for the Final Report. Address dissemination of findings in the Final Report.

### **Discussion of Results**

Interpret the performance indicator rates for each measurement period, i.e., indicate whether or not target rates were met, describe whether rates improved or declined between baseline and interim, between interim and final and between baseline and final measurement periods: Overall, target rates for the annual performance indicators were not met, despite showing an increase in some areas. We show an increase in chlamydia testing in pregnant women but a decrease in syphilis testing. Rates around contraception remained stable. There was an increase in our 17P utilization rates and we exceeded the target rate of 17.5% in utilization in women between 16-24 weeks gestation.

**Explain and interpret the extent to which improvement was or was not attributable to the interventions, by interpreting quarterly or monthly intervention tracking measure trends**: When studying the process measure trends, it can be seen that our NOP submission rate has remained high. Although the overall rates have fluctuated a bit, our overall NOP submission rate remains over 50% of all known deliveries. Other measures that are showing an increase include our Case Management process measures. Outreach to high risk pregnant women has remained at an average of around 90%, however the last three quarters have all been over 96%. We have a Six Sigma project centered on Case Management engagement. These rates have also shown an increase over the last two quarters, with over a 10% increase in the last quarter alone. High NOP submissions coupled with an increase in case management engagement rates contributes to the plan being able to identify those women who are at high risk for a preterm birth which will result in more interventions being offered to prevent future preterm births.

What factors were associated with success or failure? Factors that contributed to successful interventions include increased Case Management engagement rates and increased 17P utilization rates. We continue to promote provider education on the interventions included in this PIP.

**Limitations (**For definitions and examples, refer to HEALTHY\_LOUISIANA\_PIP\_TEMPLATE\_w\_example)

As in any population health study, there are study design limitations for a PIP. Address the limitations of your project design. Examples of study limitations include: Accuracy of administrative measures that are specified using diagnosis or procedure codes are limited to the extent that providers and coders enter the correct codes; Accuracy of hybrid measures specified using chart review findings are limited to the extent that documentation addresses all services provided.

- Were there any factors that may pose a threat to the internal validity the findings? No threats were identified.
- Were there any threats to the external validity the findings? In an effort to obtain the most accurate data, we transitioned to an upgraded version of QSI (QSI-XL). During that transition, there were some issues with measure builds, however all issues have been corrected.
- **Describe any data collection challenges.** All data for the Prematurity PIP performance indicators is collected administratively, which means we are dependent on providers coding claims accurately.

### **Member Participation**

N/A

Describe methods utilized to solicit or encourage membership participation: N/A

#### **Dissemination of Findings**

• Describe the methods used to make the findings available to members, providers, or other interested parties: Findings within this PIP have been shared with other interested parties, such as Case Management, Data Analytics and Provider Network. The information is disseminated through meetings.

## 8. Next Steps

This section is completed for the Final Report. For each intervention, summarize lessons learned, system-level changes made and/or planned, and outline next steps for ongoing improvement through the PIP extension period.

In addition to the PDSA cycles being conducted on each ITM, LHCC's Case Management department conducted a Six Sigma project on the early identification of high risk pregnant members. Early identification and case management outreach and engagement are key in delivering needed services and education to our members who are at risk for preterm birth. With a focus on those who are eligible for 17P utilization, we believe the aim of 30% 17P utilization is achievable. The drivers identified along with the corresponding ITMs will help us identify those women at risk for preterm births due to other reasons, such as history of hypertension, poor social supports, mental health, substance abuse issues, etc. The quicker we are able to identify those women, the earlier we will be able to intervene in their pregnancies and offer them a variety of services which will contribute to the reduction of preterm births prior to 32 weeks gestation by 10%.

Description of Intervention	Lessons Learned	System-level changes made and/or planned	Next Steps
Notification of Pregnancy	Process measures indicated that provider submitted forms were decreasing. Providers not completing entire form – only completing basic information. Not enough information for CM to identify high-risk members.	Specific OB education was developed and implemented by the Provider Network team; provider incentives offered for NOP submission. OB education on importance of completing filling out the form in order to identify high-risk members sooner.	Continue to offer incentive for NOPs submitted by both members and providers. Continue to educate on importance of fully completing the form.
Medicaid 101	Pertinent information that needs to be delivered to providers has been identified and changed as needed. Provider education must be an on-going intervention with changes in network and changes in high delivering providers	Information that is disseminated to providers is altered as needed with new providers needing outreach and the top delivering OB/GYNs in network changing from year to year.	Academic Detailing by Medical Directors will continue, as will Provider Network outreach to OB/GYNs. As data and new studies dictate, new information will be introduced into our educational materials and discussion topics.

Enhancement of Case Management Services	Support staff was making initial outreach to members identified as high-risk. CM engagement rates began	process - clinical staff makes initial outreach and attempts to enroll all high risk members into	Developing new process to be able to outreach more members and identify potential high- risk members for
	to decline.	CM. CM engagement	enrollment in CM.
		rates began to improve.	